Photo courtesy of Biotalys
Biotalys, an agricultural technology company developing protein-based biocontrols for sustainable crop protection, announced the formal appointment of Carlo Boutton as CEO. He has served as CEO ad interim since March 2026.
"Carlo has earned the full confidence of the board through his leadership, focus on strategic execution and commitment to creating long-term value. We are pleased to confirm his appointment as chief executive officer and look forward to supporting him in the next chapter of Biotalys' development," said Biotalys Chair Simon Moroney.
Biotalys also announced its key business achievements and consolidated financial results for the first half of 2026. Biotalys implemented a strategic refocus designed to concentrate resources on its highest-priority programs and reduce annual cash burn.
The company prioritized the development and regulatory advancement of its lead biocontrol assets with the aim of commercially launching these in key markets. Biotalys made substantial regulatory progress in both the U.S. and E.U. with its first protein-based bio-control EVOCA, including obtaining state registration in Florida and making positive strides in the state registration process with the Department of Pesticide Regulation in California, paving the regulatory pathway for its commercial version EVOCA NG, which is expected to launch in the U.S. in 2029 and in Europe in 2030.
The company also achieved promising results in field trials around the globe (including independent evaluations by the University of Florida) with a second lead BioFun-6 candidate from the AGROBODY technology platform and entered into a strategic partnership with 21st.BIO, a precision fermentation technology company.
Full details on achievements during the first half of the year are available here.
"Biotalys is committed to advancing safe and effective crop protection products for a more sustainable agriculture," Boutton said. "Our team has driven considerable progress with regulators in both the United States and Europe for our first biocontrol, EVOCA, in the first half of 2026, hereby paving the way for our first commercial biofungicide EVOCA NG. Field trials in our BioFun-6 program confirm that our AGROBODY platform is able to generate effective bioactive ingredients. As we have aligned our teams and focus areas with market needs from both growers and investors, Biotalys is well-positioned to continue its path towards commercialization of our lead assets."
Boutton joined Biotalys in May 2022 as chief scientific officer, bringing more than 20 years of antibody and biochemistry leadership to the company. In his previous role as Sanofi’s global head of innovation for large molecules research, he drove the innovation strategy and managed an expansive team exploring novel technologies with antibodies, nanobodies and other biologic modalities to find pharmaceutical solutions.
Before Sanofi, he held various scientific leadership roles at Ablynx (now Sanofi) and Tibotec (a subsidiary of Johnson & Johnson), where he took part in several anti-HIV and anti-HCV drug discovery projects. At the start of his career, he contributed to the development of a platform to develop rationally designed therapeutics in the broad field of immunotherapy at Algonomics (now Lonza).
Boutton is named co-inventor on more than 20 patent applications. He obtained his M.S. and Ph.D. from the University of Leuven (Belgium), where he researched the physico-chemical behavior of proteins under high-electromagnetic fields.